- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02886832
En undersøgelse til at evaluere virkningerne af en prostatasundhedsformulering
Et åbent pilotstudie til evaluering af virkningerne af en prostatasundhedsformulering på score opnået fra den internationale prostatasymptomscore (I-PSS) spørgeskema blandt overordnede sunde mandlige deltagere, der rapporterer klager i nedre urinveje
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Denne undersøgelse er et åbent pilotstudie for at evaluere effektiviteten, sikkerheden og tolerabiliteten af en prostatasundhedsformulering. Hvert individ vil modtage en specifik dosis af formuleringen én gang dagligt.
Deltagerne vil gennemgå vurderinger af blodprøver, vitale tegn, kropsvægt, BMI med udfyldelse af spørgeskemaer.
Det primære formål med undersøgelsen er at vurdere effektiviteten af prostatasundhedsformuleringen på I-PSS-score.
Sekundære mål:
- At vurdere I-PSS "Livskvalitet" spørgsmålscore
- At vurdere PSA-niveauet
- At vurdere IIEF-5 spørgeskemascore
- At vurdere kropsvægt
- At vurdere BMI
- At vurdere scoren på et spørgeskema for sundhedsrelateret livskvalitet
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Life Extension Clinical Research, Inc.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Primære inklusionskriterier:
- Ambulant, mand, 45-75 år
- Har et BMI på 20-35
- At have en I-PSS-score på 1-7
- Generelt sund og uden problemer med fordøjelsen eller optagelsen af mad
Primære ekskluderingskriterier:
- Ude af stand til at opretholde stabile trænings- og kostvaner gennem hele undersøgelsen
- Anamnese med en eller flere af følgende medicinske tilstande: diabetes, prostata- og/eller blærekræft, arytmi, hypotension, hypertension (medmindre på en stabil dosis af antihypertensiv medicin i 3 måneder før baseline/screening og sandsynligvis ikke ændres medicin eller dosis i undersøgelsesperioden), kronisk inflammatorisk eller autoimmun sygdom, gastrointestinal sygdom (inklusive gastroøsofageal refluks og mavesår), galdevejsobstruktion (tidligere eller nuværende), kardiovaskulær sygdom, hyper- eller hypothyroidisme (medmindre på en stabil dosis af medicin for 3 måneder før baseline/screening og sandsynligvis ikke ændre medicin eller dosis i løbet af undersøgelsesperioden), lever- eller nyresygdom, ødem med eller uden kongestiv hjertesvigt, slagtilfælde, blødningsforstyrrelser, søvnapnø, søvnløshed, migrænehovedpine (inden for 3 måneder) før baseline/screening), psykiatriske lidelser, angstlidelse, kendt eller formodet østrogenafhængig neoplasi, historie med trombose eller emboli, enhver neurologisk lidelse, der kunne give kognitiv forringelse, inklusive Parkinsons sygdom, slagtilfælde, intrakraniel blødning, hovedskade, hjernetumor( s), hydrocephalus ved normalt tryk eller tegn på delirium, forvirring, demens eller Alzheimers sygdom eller andre tilstande, der ville udelukke deltagelse i undersøgelsen i bedømmelsen af PI/Sub-Investigator (Sub-I)
- Har taget en 5-alfa-reduktasehæmmer, alfa- eller betablokkermedicin, diuretika, calciumkanalblokkere, tricykliske antidepressiva eller antikolinerge midler 90 dage før baseline/screening
- Har taget testosteronerstatningsterapi i mindre end 3 måneder eller vil sandsynligvis ikke opretholde det samme terapeutiske regime (inklusive dosis) i hele undersøgelsesperioden
- Efter at have taget pygeumekstrakt, beta-sitosterol, melatonin, lycopen eller bor og uvillig til at stoppe brugen 30 dage før tilmelding (medmindre det er tilladt at tilmelde sig PI/Sub-I's bedømmelse)
- Efter at have taget savpalme, græspollenekstrakt, blomsterpollenekstrakt, brændenældeekstrakt og dværgnældeekstrakt, græskarfrøolieekstrakt, lignanekstrakt eller boswellia serrata-ekstrakt mindre end 6 måneder før screening og uvillig til at stoppe brugen 30 dage før tilmelding (medmindre tilladt at tilmelde sig PI/Sub-I's dom)
- Indtager i øjeblikket et produkt, der indeholder olestra og er uvillig til at stoppe brugen 30 dage før tilmelding
- Har taget anxiolytika og beroligende hypnotika, antikonvulsiva, antineoplastika, anti-migræne medicin(er), opioidanalgetika, monoaminoxidasehæmmere (MAO-hæmmere), phosphodiesterasehæmmere, adenosin-genoptagelseshæmmere, dopaminagonister, dopaminagonister, dopamin-agonister, dopamin-agonister eller 3 dage før /screening
- At have taget en antiinflammatorisk medicin, antihistamin eller dekongestant inden for 14 dage før baseline/screening
- At have haft en kirurgisk procedure, herunder prostata- eller blærekirurgi, som ville udelukke undersøgelsesdeltagelse i bedømmelsen af PI/Sub-I
- Har nogen blodkoagulationsforstyrrelser, anæmi, vitamin K-mangel eller tager antikoagulantia og blodpladehæmmende medicin(er)
- Har unormale laboratorietestværdier for screening: bilirubin > 2,5 x ULN, AST/SGOT og ALT/SGPT > 2,5 x ULN, serumkreatinin > 1,5 mg/dL, PSA > 4 ng/ml, unormal urinanalyse (positive proteiner, leukocytter, okkult blod og nitritter) eller andre laboratorietestresultater, der ville udelukke undersøgelsesdeltagelse i bedømmelsen af PI/Sub-I
- Indtager i øjeblikket mere end 6 standard alkoholholdige drikkevarer om ugen (en standard alkoholholdig drik er defineret som en flaske/dåse øl, et glas vin eller en ounce hård spiritus)
- Ude af stand til eller uvillig til at afholde sig fra at indtage alkohol inden for to timer efter indtagelse af undersøgelsesproduktet
- Anamnese med kendt alkohol- eller stofmisbrug (f.eks. opiater, benzodiazepiner eller amfetaminer)
- Har røget cigaret, elektronisk cigaret, cigar, pibe eller fritidsstof inden for de seneste 30 dage
- Anamnese med allergi eller følsomhed over for enhver komponent i undersøgelsesproduktet (såvel som fyrretræ)
- Deltagelse i en anden undersøgelse inden for 30 dage før baseline/screening
- Kan eller vil ikke undgå at indtage grapefrugt
- At have en pacemaker eller andet internt medicinsk udstyr
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Prostatasundhedsformulering
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Gennemsnitlig ændring på I-PSS-score
Tidsramme: 60 dage
|
60 dage
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Gennemsnitlig ændring på I-PSS Quality of Life-spørgsmålsscore
Tidsramme: 60 dage
|
60 dage
|
|
Gennemsnitlig ændring i PSA-niveauet
Tidsramme: 60 dage
|
60 dage
|
|
Gennemsnitlig ændring på IIEF-5 spørgeskemascore
Tidsramme: 60 dage
|
60 dage
|
|
Gennemsnitlig ændring i kropsvægt
Tidsramme: 60 dage
|
60 dage
|
|
Gennemsnitlig ændring i BMI
Tidsramme: 60 dage
|
60 dage
|
|
Gennemsnitlig ændring i scoren på et spørgeskema for sundhedsrelateret livskvalitet
Tidsramme: 60 dage
|
60 dage
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Steven Joyal, M.D., Life Extension
Publikationer og nyttige links
Generelle publikationer
- Andersen LP, Gogenur I, Rosenberg J, Reiter RJ. The Safety of Melatonin in Humans. Clin Drug Investig. 2016 Mar;36(3):169-75. doi: 10.1007/s40261-015-0368-5.
- Mace, A.E. (1964), Sample Size Determination, New York: Reinhold Publishing Corporation
- Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr. 2003 May;57(5):681-92. doi: 10.1038/sj.ejcn.1601598.
- Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993 Oct;2(3):217-27. doi: 10.1002/hec.4730020305.
- Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012 May;52(4):437-45. doi: 10.1111/j.1600-079X.2011.00958.x. Epub 2012 Feb 21.
- Shenouda NS, Sakla MS, Newton LG, Besch-Williford C, Greenberg NM, MacDonald RS, Lubahn DB. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007 Feb;31(1):72-81. doi: 10.1007/s12020-007-0014-y.
- Larre S, Camparo P, Comperat E, Boulbes D, Haddoum M, Baulande S, Soularue P, Costa P, Cussenot O. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012 May;14(3):499-504. doi: 10.1038/aja.2011.132. Epub 2011 Dec 26.
- Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549-57; discussion 1564. doi: 10.1016/s0022-5347(17)36966-5.
- Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006 Feb 18;332(7538):385-93. doi: 10.1136/bmj.38731.532766.F6. Epub 2006 Feb 10.
- Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26. doi: 10.1038/sj.ijir.3900472.
- Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004 Sep-Oct;22(5):415-20. doi: 10.1016/j.urolonc.2004.05.009.
- Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008 Jan;138(1):49-53. doi: 10.1093/jn/138.1.49.
- Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 Mar;22(3):659-61. doi: 10.1096/fj.07-9574LSF. Epub 2007 Oct 17.
- Adjakly M, Ngollo M, Dagdemir A, Judes G, Pajon A, Karsli-Ceppioglu S, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D. Prostate cancer: The main risk and protective factors-Epigenetic modifications. Ann Endocrinol (Paris). 2015 Feb;76(1):25-41. doi: 10.1016/j.ando.2014.09.001. Epub 2015 Jan 13.
- Aguilar F, Autrup H, Barlow S et al. Scientific Opinion of the Panel onf Food Additives, Flavourings, Processing Adids and Materials in Contact with Food on a request from the Commission on the safety in use of lycopene as a food colour. The EFSA Journal. 2008;675:1-66.
- Andro M, Riffaud J. Pygeum Africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Current Therapeutic Research. 1995;56(8):796-817.
- Assar EA, Vidalle MC, Chopra M, Hafizi S. Lycopene acts through inhibition of IkappaB kinase to suppress NF-kappaB signaling in human prostate and breast cancer cells. Tumour Biol. 2016 Jul;37(7):9375-85. doi: 10.1007/s13277-016-4798-3. Epub 2016 Jan 16.
- Awad AB, Chen YC, Fink CS, Hennessey T. beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. Anticancer Res. 1996 Sep-Oct;16(5A):2797-804.
- Awad AB, Chinnam M, Fink CS, Bradford PG. beta-Sitosterol activates Fas signaling in human breast cancer cells. Phytomedicine. 2007 Nov;14(11):747-54. doi: 10.1016/j.phymed.2007.01.003. Epub 2007 Mar 12.
- Awad AB, Gan Y, Fink CS. Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer. 2000;36(1):74-8. doi: 10.1207/S15327914NC3601_11.
- Awad AB, Roy R, Fink CS. Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells. Oncol Rep. 2003 Mar-Apr;10(2):497-500.
- Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets. 2012 Jun;11(3):207-21. doi: 10.2174/187152812800392715.
- Barlet A, Albrecht J, Aubert A, Fischer M, Grof F, Grothuesmann HG, Masson JC, Mazeman E, Mermon R, Reichelt H, et al. [Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study]. Wien Klin Wochenschr. 1990 Nov 23;102(22):667-73. German.
- Barranco WT, Eckhert CD. Boric acid inhibits human prostate cancer cell proliferation. Cancer Lett. 2004 Dec 8;216(1):21-9. doi: 10.1016/j.canlet.2004.06.001.
- Barranco WT, Eckhert CD. Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer. 2006 Mar 27;94(6):884-90. doi: 10.1038/sj.bjc.6603009.
- Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995 Jun 17;345(8964):1529-32. doi: 10.1016/s0140-6736(95)91085-9.
- Bolt HM, Basaran N, Duydu Y. Human environmental and occupational exposures to boric acid: reconciliation with experimental reproductive toxicity data. J Toxicol Environ Health A. 2012;75(8-10):508-14. doi: 10.1080/15287394.2012.675301.
- Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin. 1998;14(3):127-39. doi: 10.1185/03007999809113352.
- Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999 Sep;54(3):473-8. doi: 10.1016/s0090-4295(99)00147-8.
- Chen P, Zhang W, Wang X, Zhao K, Negi DS, Zhuo L, Qi M, Wang X, Zhang X. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(33):e1260. doi: 10.1097/MD.0000000000001260.
- Cui Y, Winton MI, Zhang ZF, Rainey C, Marshall J, De Kernion JB, Eckhert CD. Dietary boron intake and prostate cancer risk. Oncol Rep. 2004 Apr;11(4):887-92.
- Culver B, Hubbard S. 1996. Inorganic boron health effects in humans: An aid to risk assessment and clinical judgment. J Trace Elem Exp Med 9:175-184.
- Devaraj S, Mathur S, Basu A, Aung HH, Vasu VT, Meyers S, Jialal I. A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. J Am Coll Nutr. 2008 Apr;27(2):267-73. doi: 10.1080/07315724.2008.10719699.
- DHHS. U. S. Department of Health and Human Services. Center for Drug Evaluation and Research. Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapetuics in Adult Heathy Volunteers. 7/2005. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed 6/21/2016.
- Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004 Mar;171(3):1199-202. doi: 10.1097/01.ju.0000110442.47593.ea.
- Gallardo-Williams MT, Chapin RE, King PE, Moser GJ, Goldsworthy TL, Morrison JP, Maronpot RR. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol. 2004 Jan-Feb;32(1):73-8. doi: 10.1080/01926230490260899.
- Grattan BJ Jr. Plant sterols as anticancer nutrients: evidence for their role in breast cancer. Nutrients. 2013 Jan 31;5(2):359-87. doi: 10.3390/nu5020359.
- Gupta R, Sharma AK, Dobhal MP, Sharma MC, Gupta RS. Antidiabetic and antioxidant potential of beta-sitosterol in streptozotocin-induced experimental hyperglycemia. J Diabetes. 2011 Mar;3(1):29-37. doi: 10.1111/j.1753-0407.2010.00107.x.
- Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gogenur I. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014 Jun;145(3):683-95. doi: 10.1007/s10549-014-2962-2. Epub 2014 Apr 23.
- Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood). 2002 Nov;227(10):920-3. doi: 10.1177/153537020222701013.
- Heindel JJ, Price CJ, Field EA, Marr MC, Myers CB, Morrissey RE, Schwetz BA. Developmental toxicity of boric acid in mice and rats. Fundam Appl Toxicol. 1992 Feb;18(2):266-77. doi: 10.1016/0272-0590(92)90055-m.
- Henderson K, Stella SL, Kobylewski S, Eckhert CD. Receptor activated Ca(2+) release is inhibited by boric acid in prostate cancer cells. PLoS One. 2009 Jun 23;4(6):e6009. doi: 10.1371/journal.pone.0006009.
- Hevia D, Gonzalez-Menendez P, Quiros-Gonzalez I, Miar A, Rodriguez-Garcia A, Tan DX, Reiter RJ, Mayo JC, Sainz RM. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res. 2015 Mar;58(2):234-50. doi: 10.1111/jpi.12210. Epub 2015 Feb 7.
- Ilic D. Lycopene for the prevention and treatment of prostate disease. Recent Results Cancer Res. 2014;202:109-14. doi: 10.1007/978-3-642-45195-9_13.
- Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci. 1999 Aug;50(2):271-9. doi: 10.1093/toxsci/50.2.271.
- Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer. 2005 Mar 1;113(6):1010-4. doi: 10.1002/ijc.20667.
- Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010 Aug;49(1):60-8. doi: 10.1111/j.1600-079X.2010.00767.x. Epub 2010 May 27.
- Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2011 Mar;50(2):140-9. doi: 10.1111/j.1600-079X.2010.00823.x. Epub 2010 Nov 9.
- Kava. In: Natural Medicines Comprehensive Database. Stockton, CA: Therapeutic Research Faculty. [Updated January 6, 2016; Accessed May 24, 2016]. http://naturaldatabase.therapeuticresearch.com/nd/Search.aspx?cs=OSU&s=ND&pt=100&id=872&ds =&name=KAVA&searchid=37784702
- Kim CH, Yoo YM. Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells. Korean J Physiol Pharmacol. 2010 Dec;14(6):365-9. doi: 10.4196/kjpp.2010.14.6.365. Epub 2010 Dec 31.
- Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997 Sep;80(3):427-32.
- Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood). 2002 Nov;227(10):881-5. doi: 10.1177/153537020222701007.
- Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50.
- Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res. 2000 Jun;28(3):201-9. doi: 10.1007/s002409900098.
- Li D, Chen L, Zhao W, Hao J, An R. MicroRNA-let-7f-1 is induced by lycopene and inhibits cell proliferation and triggers apoptosis in prostate cancer. Mol Med Rep. 2016 Mar;13(3):2708-14. doi: 10.3892/mmr.2016.4841. Epub 2016 Feb 2.
- Litovitz TL, Klein-Schwartz W, Oderda GM, Schmitz BF. Clinical manifestations of toxicity in a series of 784 boric acid ingestions. Am J Emerg Med. 1988 May;6(3):209-13. doi: 10.1016/0735-6757(88)90001-0.
- Lomenick B, Shi H, Huang J, Chen C. Identification and characterization of beta-sitosterol target proteins. Bioorg Med Chem Lett. 2015 Nov 1;25(21):4976-4979. doi: 10.1016/j.bmcl.2015.03.007. Epub 2015 Mar 11.
- Murray FJ. A comparative review of the pharmacokinetics of boric acid in rodents and humans. Biol Trace Elem Res. 1998 Winter;66(1-3):331-41. doi: 10.1007/BF02783146.
- Murray FJ. A human health risk assessment of boron (boric acid and borax) in drinking water. Regul Toxicol Pharmacol. 1995 Dec;22(3):221-30. doi: 10.1006/rtph.1995.0004.
- Paroni R, Terraneo L, Bonomini F, Finati E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ, Rezzani R, Samaja M. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res. 2014 Aug;57(1):43-52. doi: 10.1111/jpi.12142. Epub 2014 May 20.
- Pizzorno L. Nothing Boring About Boron. Integr Med (Encinitas). 2015 Aug;14(4):35-48.
- Quiles MT, Arbos MA, Fraga A, de Torres IM, Reventos J, Morote J. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate. 2010 Jul 1;70(10):1044-53. doi: 10.1002/pros.21138.
- Risk Profile. Beta-sitosterol. CAS No. 83-46-5. http://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_betasitosterol.11370/binary/Risk%20Profile%20Beta-Sitosterol. 8/27/2012. Accessed 6/20/2016.
- Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005 Apr 1;63(1):29-43. doi: 10.1002/pros.20155.
- Shao A, Hathcock JN. Risk assessment for the carotenoids lutein and lycopene. Regul Toxicol Pharmacol. 2006 Aug;45(3):289-98. doi: 10.1016/j.yrtph.2006.05.007. Epub 2006 Jun 30.
- Sohn EJ, Won G, Lee J, Lee S, Kim SH. Upregulation of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells. J Cancer. 2015 Jan 1;6(1):19-28. doi: 10.7150/jca.9591. eCollection 2015.
- Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):109-23. doi: 10.2174/187221411799015408.
- Stokinger HE. 1981. The halogens and nonmetals boron and silicon. In: Clayton GD, Clayton FE, eds. Patty's Industrial Hygiene and Toxicology, Vol. 2B. New York: John Wiley and Sons. Pp. 2978- 3005.
- Sugaya K, Nishijima S, Miyazato M, Kadekawa K, Ogawa Y. Effects of melatonin and rilmazafone on nocturia in the elderly. J Int Med Res. 2007 Sep-Oct;35(5):685-91. doi: 10.1177/147323000703500513.
- Ulbricht CE. An Evidence-Based Systematic Review of Beta-Sitosterol, Sitosterol (22,23- dihydrostigmasterol, 24-ethylcholesterol) by the Natural Standard Research Collaboration. J Diet Suppl. 2016;13(1):35-92. Epub 2015 Aug 13.
- von Holtz RL, Fink CS, Awad AB. beta-Sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer. 1998;32(1):8-12. doi: 10.1080/01635589809514709.
- Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014 Jun 18;9:947-61. doi: 10.2147/CIA.S65625. eCollection 2014.
- Wang Y, Jacobs EJ, Newton CC, McCullough ML. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Int J Cancer. 2016 Jun 15;138(12):2846-55. doi: 10.1002/ijc.30027. Epub 2016 Feb 23.
- Wertz K. Lycopene effects contributing to prostate health. Nutr Cancer. 2009;61(6):775-83. doi: 10.1080/01635580903285023.
- Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys. 2004 Oct 1;430(1):127-34. doi: 10.1016/j.abb.2004.04.023.
- Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1998(1):CD001044. doi: 10.1002/14651858.CD001044.
- Wilt TJ, MacDonald R, Ishani A. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999 Jun;83(9):976-83. doi: 10.1046/j.1464-410x.1999.00026.x.
- Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, Willett WC, Giovannucci E. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):260-9. doi: 10.1158/1055-9965.epi-03-0012.
- Zhao Y, Chang SK, Qu G, Li T, Cui H. Beta-sitosterol inhibits cell growth and induces apoptosis in SGC-7901 human stomach cancer cells. J Agric Food Chem. 2009 Jun 24;57(12):5211-8. doi: 10.1021/jf803878n.
- Hirsh SP, Pons M, Joyal SV, Swick AG. Self-Assessed Benefits of a Prostate Health Formulation on Nocturia in Healthy Males With Mild Lower Urinary Tract Symptoms: An Open Label Study. Glob Adv Health Med. 2020 Nov 27;9:2164956120973639. doi: 10.1177/2164956120973639. eCollection 2020.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- CL089
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Prostata sundhed
-
Shanghai Mental Health CenterRekrutteringMental Health LiteracyKina
-
3-C Institute for Social DevelopmentUniversity of WashingtonAfsluttetMental Health ServicesForenede Stater
-
Colgate PalmoliveAfsluttetOral Health LiteracyIndien
-
European University CyprusAfsluttet
-
Universidad de ValparaisoRekrutteringMental Health LiteracyChile, Ecuador
-
Transcultural Psychosocial Organization NepalKing's College LondonRekrutteringMental Health WellnessNepal
-
Hospital Miguel ServetAktiv, ikke rekrutterendeMental Health WellnessSpanien
-
Wake Forest University Health SciencesAfsluttet
-
Fonterra Research CentreSun GenomicsAfsluttet
-
City University of Hong KongStanford University; Harvard UniversityAfsluttetMental Health WellnessColombia, Indonesien, Sydafrika, Ukraine
Kliniske forsøg med Prostatasundhedsformulering
-
Fresenius Medical Care North AmericaMedical Nutrition USA, Inc.Afsluttet
-
Brigham and Women's HospitalAfsluttetTilsyneladende overskud af mineralokortikoid (AME)Forenede Stater
-
EMD SeronoAfsluttetMultipel scleroseForenede Stater, Canada, Tyskland, Italien, Spanien, Sverige
-
Florida State UniversityUniversity of North Carolina, Chapel Hill; University of GeorgiaTilmelding efter invitationKardiovaskulær sygdom risikoreduktionForenede Stater
-
Icahn School of Medicine at Mount SinaiNoom Inc.Afsluttet
-
Pack HealthGlaxoSmithKline; University of WashingtonRekrutteringMyelomatose | Tilbagefaldende hæmatologisk malignitetForenede Stater
-
BaycrestAfsluttetDemens | Mild kognitiv svækkelse | Forebyggelse af demens | Subjektiv kognitiv svækkelse | Præ-demensCanada
-
Ponce Medical School Foundation, Inc.University of Rochester; University of Puerto Rico Medical Sciences CampusRekrutteringMentalt helbred | Depression Angstlidelse | Mental SundhedsplejePuerto Rico
-
Radicle ScienceAfsluttetMavesmerter | Fordøjelse | GI lidelserForenede Stater
-
Radicle ScienceAfsluttet